STAT6 Degrader Program (GlobeNewswire) - Nov 4, 2025 - "The Company has completed enrollment and dosing in the KT-621 BroADen Phase 1b trial, an open label study in patients with moderate to severe AD, with data expected to be reported in December 2025...The KT-621 BROADEN2 Phase 2b trial in AD has been initiated with data expected by mid-2027...The Company is on track to initiate BREADTH, a Phase 2b trial in moderate to severe asthma patients, in the first quarter of 2026."
New P2b trial • P1 data • P2b data • Asthma • Atopic Dermatitis • Immunology
|